Liver Disease Diagnosis and Treatment · Journal article

Ketogenesis as a Metabolic Checkpoint in MASLD: Implications for Disease Progression and Therapy

Metabolites · September 8, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a mechanistic review that proposes ketogenesis as a central metabolic checkpoint linking fatty acid oxidation, mitochondrial function and immune signalling in MASLD progression. The authors hypothesize that impaired ketogenic capacity during MASLD promotes acetyl-CoA accumulation, oxidative stress and lipotoxic synthesis while reducing protective β-hydroxybutyrate signalling, but the evidence presented is conceptual rather than empirical.

What was studied

Journal article. Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) across the disease spectrum from simple steatosis to cirrhosis and hepatocellular carcinoma.

Key findings

Ketogenesis is proposed as a key regulator of hepatic metabolic homeostasis coordinating mitochondrial substrate utilization and systemic metabolic adaptation. β-hydroxybutyrate functions as a signalling metabolite modulating inflammation, oxidative stress, mitochondrial function and epigenetic regulation. Ketogenic capacity becomes progressively impaired during MASLD despite increased fatty acid delivery, promoting mitochondrial acetyl-CoA accumulation and oxidative stress.

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

This review identifies ketogenesis as a potential therapeutic target to prevent MASLD progression, but readers should note that this framework is mechanistic and has not been validated through clinical trials or interventional studies reporting patient-relevant outcomes.

Plain-language summary

This is a mechanistic review proposing ketogenesis as a regulatory hub in MASLD pathogenesis; it raises a conceptual framework rather than reporting empirical evidence of a clinical intervention or outcome.

Clinical bottom line

Caveats

No quantitative data, effect sizes, or statistical comparisons reported; literature synthesis only.
No clinical trials, patient cohorts, or empirical outcome measures presented.
Therapeutic potential of restoring ketogenesis is discussed conceptually but not demonstrated through clinical evidence.
Generalizability to specific MASLD patient subgroups or stages not addressed.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Narrative review; no primary empirical data collection or analysis reported.

Directness

limited

Discusses mechanistic pathways and ketogenesis signalling; no clinical endpoints or patient outcomes measured.

Consistency

insufficient

Synthesis of existing literature; no comparison of conflicting results or meta-analysis reported.

Risk of bias

insufficient

Review article; no study quality assessment, blinding, or bias mitigation measures detailed.

Sample adequacy

insufficient

No patient cohort, trial population, or sample size; literature synthesis only.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, encompassing a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis and hepatocellular carcinoma. Increasing evidence indicates that disease progression is driven not by hepatic triglyceride accumulation alone but by the metabolic partitioning of excess fatty acids between adaptive and maladaptive pathways. Ketogenesis, traditionally viewed as a fasting-induced mechanism for disposing of excess acetyl-CoA, is now recognized as a key regulator of hepatic metabolic homeostasis, coordinating mitochondrial substrate utilization, carbon flux and systemic metabolic adaptation. In addition to serving as oxidative fuels, ketone bodies, particularly β-hydroxybutyrate, function as signalling metabolites that modulate inflammation, oxidative stress, mitochondrial function and epigenetic regulation. Despite increased fatty acid delivery in obesity and insulin resistance, ketogenic capacity becomes progressively impaired during MASLD, promoting mitochondrial acetyl-CoA accumulation, oxidative stress and diversion of carbon toward lipotoxic lipid synthesis while reducing protective β-hydroxybutyrate signalling. This review examines ketogenesis as an integrative metabolic checkpoint linking fatty acid oxidation, lipid metabolism, mitochondrial function and immune signalling in MASLD. We discuss how impaired ketogenic flux contributes to hepatocellular injury, fibrosis and metabolic inflexibility, and evaluate the therapeutic potential of restoring ketogenesis to prevent disease progression.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Ambrin Farizah BabuLiver Disease Diagnosis and Treatment